Murphy Pohlad Asset Management LLC Decreases Stock Position in Pfizer Inc. $PFE

Murphy Pohlad Asset Management LLC lessened its stake in Pfizer Inc. (NYSE:PFE) by 5.7% in the second quarter, Holdings Channel reports. The fund owned 116,895 shares of the biopharmaceutical company’s stock after selling 7,070 shares during the quarter. Murphy Pohlad Asset Management LLC’s holdings in Pfizer were worth $2,834,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. GKV Capital Management Co. Inc. purchased a new position in shares of Pfizer during the 1st quarter valued at approximately $27,000. Curio Wealth LLC boosted its stake in shares of Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,098 shares during the last quarter. Bayforest Capital Ltd purchased a new position in shares of Pfizer during the 1st quarter valued at approximately $28,000. North Capital Inc. purchased a new position in shares of Pfizer during the 1st quarter valued at approximately $28,000. Finally, Harbor Asset Planning Inc. purchased a new position in shares of Pfizer during the 2nd quarter valued at approximately $29,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Price Performance

Shares of NYSE PFE opened at $24.30 on Friday. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $28.64. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The business’s fifty day moving average price is $24.80 and its two-hundred day moving average price is $24.25. The firm has a market capitalization of $138.15 billion, a PE ratio of 12.93, a P/E/G ratio of 0.81 and a beta of 0.55.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period last year, the company earned $0.60 earnings per share. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 7.1%. Pfizer’s dividend payout ratio (DPR) is currently 91.49%.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. UBS Group reiterated a “neutral” rating and set a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Citigroup raised their price objective on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Finally, Bank of America raised their price objective on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and an average target price of $28.13.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.